Encorafenib
Brand: Braftovi (global)
Anticancer
BRAF inhibitor (V600E/K)
Pharmacokinetics
| Half-life | 6 hours |
| Tmax | 3 h |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Used with Binimetinib. Has longer target residence time than Vemurafenib/Dabrafenib. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
QT prolongation, ocular toxicity, hepatotoxicity, fatigue
Contraindications:
Severe heart rhythm disorders
Precautions:
Monitor ECG and LFTs; ophthalmology evaluation if visual symptoms.